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Dear Editor,
The World Health Organisation (WHO) Essential
Medicines List (EML) [1] informs countries about the
minimum medicine items necessary to meet priority
health needs of the population and guide national and
institutional medicine lists, especially in Low Resource
Income Countries. The current EML under medicines
for ‘joint diseases in children’ does not reflect current
best practice [2] and an important theme of work from
the Paediatric Global Musculoskeletal Health Task
Force (TF) [3] is to revise the listing for medicines
relevant to paediatric rheumatic diseases.
Healthcare professionals working in paediatric
rheumatology and who are TF members were invited
to take part in an anonymous online survey WHO
EML to explore which drugs they deemed to be ‘essen-
tial’ and ‘ideal’ for the clinical practice in their context.
No reminders to the survey were sent. We had 97
responders, from 43 countries across all continents
and mainly from low resource countries (Asia n = 51/
97). Respondents had a range of 1–35 years of clinical
practice and included consultant grade paediatric
rheumatologists (n = 77), consultant general paediatri-
cians with interest in rheumatology (n = 13), paediatric
rheumatology trainees (n = 3), adult rheumatologists
(n = 3) and a nurse working in paediatric rheumatol-
ogy (n = 1). Survey data were analysed by applying
descriptive statistics and free-text comments were
analysed following standard procedures for qualitative
analysis [4].
Most respondents (n = 70/97, 72%) reported that a
revised EML would very likely improve access to med-
icines in their country, improve drug accessibility
within their clinical practice, provide assistance when
negotiating with healthcare agencies or insurance
companies and further increase awareness about
paediatric rheumatology issues. They deemed that the
EML should list the drugs in Table 1; 80% respondents
identified 5 agents as ‘essential’ (oral, intra-articular
and intravenous corticosteroids, NSAIDS, Hydroxy-
chloroquine and Methotrexate [oral and subcutane-
ous]) and a wide range of synthetic and biologic
DMARDS as well as other immunosuppressive agents
be included. This ‘cut off’ of 80% will form the basis of
the TF application to the WHO to revise the EML
with the submission planned for late 2020. It is our
hope that raising awareness and improving access to
appropriate therapy will lead to better outcomes for
children with rheumatic diseases globally and allow
for a targeted treatment approach [5].
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Oral prednisolone 100% 92%
Oral NSAIDs 99% 93%
Hydroxychloroquine 98% 88%
Intravenous Methylprednisolone 98% 83%
Methotrexate oral 96% 81%
Mycophenolate Mofetil 95% 77%
Azathioprine 94% 71%
Methotrexate subcutaneous 91% 80%







Intravenous Tocilizumab 86% 63%
Oral prednisolone (soluble) 86% 55%
Ciclosporin 85% 52%
Sulphasalazine 84% 51%











Oral cyclophosphamide 41% 16%
Inhaled analgesia (nitrous oxide) 36% 15%
Thalidomide 34% 8%
Total Respondents: 97
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